Development of renal disease in people at high cardiovascular risk : results of the HOPE randomized study . 
<br>
<br> In people with diabetes , renal disease tends to progress from microalbuminuria to clinical proteinuria to renal insufficiency . Little evidence has been published for the nondiabetic population . This study retrospectively analyzed changes of proteinuria over 4.5 yr in the HOPE ( Heart Outcomes and Prevention Evaluation ) study , which compared ramipril 's effects to placebo in 9297 participants , including 3577 with diabetes and 1956 with microalbuminuria . This report is restricted to 7674 participants with albuminuria data at baseline and at follow - up . Inclusion criteria were known vascular disease or diabetes plus one other cardiovascular risk factor , exclusion criteria included heart failure or known impaired left ventricular function , dipstick - positive proteinuria ( > 1 + ) , and serum creatinine > 2.3 mg / dl ( 200 microM ) . <font color="blue">Baseline_1</font> <font color="blue">microalbuminuria_1</font> <font color="blue">predicted_1</font> <font color="blue">subsequent_1</font> <font color="blue">clinical_2</font> <font color="blue">proteinuria_2</font> <font color="blue">for_1</font> <font color="blue">the_1</font> <font color="blue">study_1</font> <font color="blue">participants_1</font> <font color="blue">overall_1</font> ( adjusted odds ratio [ OR ] , 17.5 ; 95% confidence interval [ CI ] , 12.6 to 24.4 ) , in participants without diabetes ( OR , 16.7 ; 95% CI , 8.6 to 32.4 ) , and in participants with diabetes ( OR , 18.2 ; 95% CI , 12.4 to 26.7 ) . Any <font color="blue">progression_2</font> <font color="blue">of_2</font> <font color="blue">albuminuria_3</font> ( defined as new microalbuminuria or new clinical proteinuria ) occurred in 1859 participants ; 1542 developed new <font color="blue">microalbuminuria_1</font> <font color="blue">,_1</font> and 317 participants developed <font color="blue">clinical_1</font> <font color="blue">proteinuria_1</font> <font color="blue">._1</font> Ramipril reduced the <font color="blue">risk_1</font> <font color="blue">for_1</font> <font color="blue">any_1</font> <font color="blue">progression_2</font> ( OR , 0.87 ; 95% CI , 0.78 to 0.97 ; P = 0.0146 ) . People without and with diabetes who are at <font color="blue">high_1</font> <font color="blue">risk_1</font> <font color="blue">for_1</font> <font color="blue">cardiovascular_1</font> <font color="blue">disease_1</font> are also at risk for a progressive rise in <font color="blue">albuminuria_1</font> <font color="blue">._1</font> <font color="blue">Microalbuminuria_1</font> itself predicts clinical proteinuria in nondiabetic and in diabetic people . Ramipril <font color="blue">prevents_1</font> <font color="blue">or_1</font> <font color="blue">delays_1</font> <font color="blue">the_1</font> <font color="blue">progression_1</font> <font color="blue">of_1</font> <font color="blue">albuminuria_1</font> <font color="blue">._1</font>